首页膀胱肿瘤诊断证据详情

The association of pretreatment serum albumin with outcomes in bladder cancer: a meta-analysis

原文: 2018 年 发布于 Medicine 14 卷 第 6 期 503-510 浏览量:240次

作者: Li J. Cheng Y. Liu G. Ji Z.

作者单位: Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, Guangdong, China. Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, Guangdong, China. junxingchen@hotmail.com. Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, Guangdong, China. chenlingwu@hotmail.com.

归属分类: 膀胱肿瘤诊断证据

DOI: 10.3389/fonc.2021.653491

关键词: Carcinoma/etiology/pathology Case-Control Studies Chronic Disease Humans Risk Urinary Bladder/pathology Urinary Bladder Neoplasms/*etiology/pathology Urinary Tract/*pathology Urinary Tract Infections/*complications/pathology

文献简介

Objectives: Patients with type 2 diabetes mellitus (T2DM) have a higher incidence of bladder cancer (BC); however, the evidence underlining the association between pioglitazone use and BC risk remains inconclusive. We conducted a systematic review and meta-analysis of observational studies to investigate the effect of pioglitazone on risk of BC in T2DM patients. Methods: We searched all publications regarding risk of BC with pioglitazone use through PubMed, Web of Science and Cochrane library databases from inception to March, 2017. Pooled hazard ratio (HR) and 95% confidence interval (CI) were calculated using a random-effect, generic inverse variance method. Results: Total 15 observational (9 cohort and 6 case-control) studies were meta-analyzed. The pooled results showed a significant association between risk of BC and pioglitazone use (HR 1.20, 95% CI 1.09-1.31; P < 0.0001; I-2 = 4%). In subgroup analysis, cumulative dose of pioglitazone (- and > mg) showed a significant association with risk of BC (HR 1.27; 95% CI 1.05-1.54; P = 0.01; I-2 = 0% and HR 1.68, 95% CI 1.36-2.08; P < 0 I-2 = 0% respectively). In addition, a significant association was seen with risk of BC and pioglitazone treatment duration (12-24 months and > 24 months) (HR 1.43; 95% CI 1.19-1.71; P = 0.0001; I-2 = 0% and HR 1.58; 95% CI 1.27-1.97; P < 0.0001; I-2 = 29% respectively). Meta-analysis of pioglitazone vs. rosiglitazone use, showed a significant association (HR 1.34; 95% CI 1.05-1.71; P = 0.02; I-2 = 0%) with BC risk and pioglitazone use. Conclusion: Pioglitazone use is associated with risk of BC in T2DM patients. Risk of bladder cancer appears to be associated with higher dose and longer duration of pioglitazone use. (c) 2017 Published by Elsevier, a division of RELX India, Pvt. Ltd on behalf of INDIACLEN.

热门文献